The use of bivalirudin in patients with renal impairment

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Robson, Richard ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; CORONARY DISEASE; HIRUDIN THERAPY; HIRUDINS; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SAFETY; TREATMENT OUTCOME;

EID: 0034567414     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Sica D. A pharmacokinetic and pharmacodynamic study of BG8967 in subjects with renal insufficiency. Study C93-313. Data on file. The Medicines Company.
2. White H and Ayland P. The influence of dose, gender and kidney function on bivalirudin pharmacokinetics and pharmacodynamics in patients undergoing percutaneous transluminal angioplasty. Study TMC 98-09. Data on file. The Medicines Company.
3. Bittl JA and the Bivalirudin Angioplasty Investigators. A multicenter, double-blind, randomized study to compare the safety and efficacy of BG8967 with heparin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Studies 92-304-1 and -2. Data on file. The Medicines Company.